申请人:Etern Biopharma (Shanghai) Co., Ltd.
公开号:EP3712151A1
公开(公告)日:2020-09-23
Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
本发明提供了一种式 I 的化合物或其药学上可接受的盐、对映体、非对映异构体、同分异构体、溶解物、同位素取代基、多晶型、原药或代谢物。还提供了一种制备式 I 化合物的方法。式I化合物对SHP2具有较高的抑制活性,因此可用于预防或治疗与SHP2相关的疾病。